

Global TIL Therapy Market (2nd Edition), 2023-2035: Distribution by Target Indication (Melanoma, Head and Neck Carcinoma, Chronic Lymphocytic Leukemia, Sarcoma, Hepatocellular Carcinoma, Breast Cancer, Acute Myeloid Leukemia and Cervical Carcinoma), Key Players and Key Geographical Regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

<https://marketpublishers.com/r/GD6529FEC45AEN.html>

Date: January 2023

Pages: 315

Price: US\$ 4,799.00 (Single User License)

ID: GD6529FEC45AEN

Abstracts

The global TIL therapy market is expected to reach USD 0.09 billion in 2023 anticipated to grow at a CAGR of 40% during the forecast period 2023-2035.

The global market for tumor infiltrating lymphocytes (TIL) therapy stands as a pivotal subset within the expansive realm of cell therapy. Projections suggest a significant upward trajectory, with an anticipated Compound Annual Growth Rate (CAGR) of 40% throughout the forecast period.

The efficacy of tumor infiltrating lymphocytes (TILs) in addressing refractory diseases has garnered robust support from an array of comprehensive studies conducted over time. TILs encompass a heterogeneous amalgamation of mononuclear lymphocytes, inclusive of T-cells, B-cells, NK cells, and macrophages meticulously extracted from the tumor microenvironment. This diverse spectrum of lymphocytes assumes a critical role in targeting and eliminating tumor cells.

Ongoing and prospective clinical research endeavors in this field are driven by the

promising outcomes derived from previous trials, predominantly focusing on a wide spectrum of solid tumors. The sustained momentum of innovation in this arena, backed by substantial financial support from investors, combined with encouraging findings from clinical trials, lays the groundwork for substantial growth within the TIL therapy market throughout the forecasted period.

Report Coverage

An executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the TIL-based therapies market in the short to mid-term and long term.

A general overview of TIL-based therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of TIL-based therapies, factors supporting the growing popularity of such therapy candidates and the challenges associated with these products.

Detailed assessment on more than 65 TIL-based therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer, phase of development, therapeutic area, popular target indications, source of T-cells, dose frequency, target patient segment and type of therapy.

An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2?2 matrix representation highlighting the KOLs shortlisted based on their contributions to this field, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers involved in the development of TIL-based therapies.

Detailed profiles of TIL-based therapies in developmental stages (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, current development status, and key clinical trial results.

An elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past

few years. Further, the partnership activity in this domain has been analyzed based on various parameters, such as type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Details on the various investments and grants that have been awarded to players focused on the development of TIL-based therapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites.

Details on the various factors that must be taken into consideration while deciding the prices of TIL-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their TIL-based therapy product can be marketed.

Brief company profiles of the leading players in the TIL-based therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to technology portfolio (if available), recent developments related to TIL-based therapy and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

An elaborate discussion on the future commercial opportunity offered by TIL-based therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II and phase II of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. It presents a detailed market segmentation based on target indications (melanoma, head and neck cancer, breast cancer, hepatocellular cancer, sarcoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and

cervical cancer), key players and key geographies (North America, Europe and Asia Pacific).

Key Market Companies

Collectis

Cellular Biomedicine Group

Iovance Biotherapeutics

Lytix Biopharma

Phio Pharmaceuticals

Contents

1. PREFACE

- 1.1. Introduction
- 1.2. Key Market Insights
- 1.3. Scope of the Report
- 1.4. Research Methodology
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Pillars of Cancer Therapy
- 3.3. Overview of Immunotherapies
- 3.4. Fundamentals of Cancer Immunotherapy
- 3.5. Classification of Cancer Immunotherapies
 - 3.5.1. By Mechanism of Action
 - 3.5.2. By Type of Target
 - 3.5.3. By Approach
 - 3.5.4. By Product Class
- 3.6. T-Cell Immunotherapies
 - 3.6.1. Historical Evolution
 - 3.6.2. Key Considerations for Developing T-Cell Immunotherapies
 - 3.6.3. Strategies Employed for the Redirection of T-Cells
 - 3.6.4. Manufacturing of Engineered T-Cells
 - 3.6.5. T-Cell Transduction and Transfection Methods
- 3.7. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
 - 3.7.1. Development History
 - 3.7.2. Development of TILs Therapy
- 3.8. Key Benefits and Roadblocks
- 3.9. Concluding Remarks

4. TIL-BASED THERAPIES: MARKET LANDSCAPE

- 4.1. Chapter Overview

4.2. TIL-based Therapies: Overall Market Landscape

4.2.1. Analysis by Type of Developer

4.2.2. Analysis by Phase of Development

4.2.3. Analysis by Therapeutic Area

4.2.4. Analysis by Key Target Indications

4.2.5. Analysis by Source of T-Cells

4.2.6. Analysis by Route of Administration

4.2.7. Analysis by Dosing Frequency

4.2.8. Analysis by Target Patient Segment

4.2.9. Analysis by Type of Therapy

4.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies

4.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies

4.3. TIL-based Therapies: Overall Developer Landscape

4.3.1. Analysis by Year of Establishment

4.3.2. Analysis by Company Size

4.3.3. Analysis by Location of Headquarters

5. CLINICAL TRIAL ANALYSIS

5.1. Chapter Overview

5.2. Scope and Methodology

5.3. TIL-based Therapies: Clinical Trial Analysis

5.3.1. Analysis by Trial Registration Year

5.3.2. Analysis by Trial Registration Year and Enrolled Patient Population

5.3.3. Analysis by Trial Status

5.3.4. Analysis by Trial Registration Year and Trial Status

5.3.5. Analysis by Trial Phase

5.3.6. Analysis by Trial Phase and Enrolled Patient Population

5.3.7. Analysis by Target Patient Segment

5.3.8. Analysis by Type of Sponsor / Collaborator

5.3.9. Analysis by Study Design

5.3.10. Most Active Industry Players: Analysis by Number of Registered Trials

5.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials

5.3.12. Word Cloud Analysis: Emerging Focus Areas

5.3.13. Analysis of Clinical Trials by Geography

5.3.14. Analysis of Enrolled Patient Population by Geography

6. KEY OPINION LEADERS

- 6.1. Chapter Overview
- 6.2. Assumptions and Key Parameters
- 6.3. Methodology
- 6.4. TIL-based Therapies: Key Opinion Leaders
 - 6.4.1. Analysis by Type of Organization
 - 6.4.2. Analysis by Affiliated Organization
 - 6.4.3. Analysis by Qualification
 - 6.4.4. Analysis by Geographical Location of KOLs
 - 6.4.5. KOL Activeness versus KOL Strength
 - 6.4.6. Most Prominent KOLs: Analysis by RA score
 - 6.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

7. TIL-BASED THERAPY PROFILES

- 7.1. Chapter Overview
- 7.2. LN-144 / Lileucel (Iovance Biotherapeutics)
 - 7.2.1. Therapy Overview
 - 7.2.2. Clinical Trial Information
 - 7.2.3. Clinical Trial Endpoints
 - 7.2.4. Clinical Trial Results
 - 7.2.5. Estimated Sales Revenues
- 7.3. LN-145 (Iovance Biotherapeutics)
 - 7.3.1. Therapy Overview
 - 7.3.2. Clinical Trial Information
 - 7.3.3. Clinical Trial Endpoints
 - 7.3.4. Clinical Trial Results
 - 7.3.5. Estimated Sales Revenues
- 7.4. ITIL-168 (Instil Bio)
 - 7.4.1. Therapy Overview
 - 7.4.2. Clinical Trial Information
 - 7.4.3. Clinical Trial Endpoints
 - 7.4.4. Clinical Trial Results
 - 7.4.5. Estimated Sales Revenues
- 7.5. LTX-315 (Lytix Biopharma)
 - 7.5.1. Therapy Overview
 - 7.5.2. Clinical Trial Information
 - 7.5.3. Clinical Trial Endpoints
 - 7.5.4. Clinical Trial Results
 - 7.5.5. Estimated Sales Revenues

8. PARTNERSHIPS AND COLLABORATIONS

8.1. Chapter Overview

8.2. Partnership Models

8.3. TIL-based Therapies: Partnerships and Collaborations

8.3.1. Analysis by Year of Partnership

8.3.2. Analysis by Type of Partnership

8.3.3. Analysis by Year of Partnership and Type of Partnership

8.3.4. Analysis by Type of Partner

8.3.5. Most Popular Products: Analysis by Number of Partnerships

8.3.6. Most Active Industry Players: Analysis by Number of Partnerships

8.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships

8.3.8. Analysis by Geography

8.3.8.1. Intercontinental and Intracontinental Agreements

8.3.8.2. International and Local Deals

9. FUNDING AND INVESTMENT ANALYSIS

9.1. Chapter Overview

9.2. Type of Funding

9.3. TIL-based Therapies: Funding and Investment Analysis

9.3.1. Analysis by Year of Investment

9.3.2. Analysis by Amount Invested

9.3.3. Analysis by Type of Funding

9.3.4. Analysis by Type of Investor

9.3.5. Most Active Players: Analysis by Number of Instances

9.3.6. Most Active Investors: Analysis by Amount Invested

9.3.7. Analysis of Amount Invested by Geography

9.3.8. Most Active Investors: Analysis by Number of Funding Instances

10. PATENT ANALYSIS

10.1. Chapter Overview

10.2. Scope and Methodology

10.3. TIL-based Therapies: Patent Analysis

10.3.1. Analysis by Patent Publication Year

10.3.2. Analysis By Patent Application Year

10.3.3. Analysis by Geography

- 10.3.4. Analysis by Type of Player
- 10.3.5. Analysis by CPC Symbols
- 10.3.6. Word Cloud Analysis: Emerging Focus Areas
- 10.3.7. Leading Players: Analysis by Number of Patents
- 10.3.8. TIL-based Therapies: Patent Benchmarking
- 10.3.9. Analysis By Patent Characteristics
- 10.3.10. TIL-based Therapies: Patent Valuation

11. CASE STUDY: CELL THERAPY MANUFACTURING

- 11.1. Chapter Overview
- 11.2. Overview of Cell Therapy Manufacturing
- 11.3. Cell Therapy Manufacturing Models
 - 11.3.1. Centralized Manufacturing Model
 - 11.3.2. Decentralized Manufacturing Model
- 11.4. Scalability of Cell Therapy Manufacturing Processes
 - 11.4.1. Scale-Up
 - 11.4.2. Scale-Out
- 11.5. Types of Cell Therapy Manufacturers
- 11.6. Key Challenges Related to Manufacturing of Cell Therapies
- 11.7. Important Factors for Cell Therapy Manufacturing
 - 11.7.1. Characterization
 - 11.7.2. Cost of Goods
- 11.8. Automation of Cell Therapy Manufacturing Process
- 11.9. Cell Therapy Manufacturing Supply Chain
- 11.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
- 11.11. Regulatory Landscape
- 11.12. Future Perspectives

12. COST PRICE ANALYSIS

- 12.1. Chapter Overview
- 12.2. Factors Contributing to the High Price of Cell / Gene Therapies
- 12.3. Pricing Models for T-Cell Immunotherapies
 - 12.3.1. Based on Associated Costs
 - 12.3.2. Based on Availability of Competing Products
 - 12.3.3. Based on Patient Segment
 - 12.3.4. Based on Opinions of Industry Experts
- 12.4. Reimbursement related Considerations for T-Cell Immunotherapies

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

13.1. Chapter Overview

13.2. Scope and Limitations

13.3. Key Assumptions and Forecast Methodology

13.4. Global TIL-Based Therapies Market, 2022-2035

13.4.1. TIL-based Therapies Market: Analysis by Target Indication

13.4.2. TIL-based Therapies Market: Analysis by Key Players

13.4.3. TIL-based Therapies Market: Analysis by Key Geographical Regions

13.4.4. Product Wise Sales Forecast

13.4.4.1. Lifileucel / LN-144 (Iovance Biotherapeutics)

13.4.4.1.1. Sales Forecast (USD Million)

13.4.4.1.2. Net Present Value (USD Million)

13.4.4.1.3. Value Creation Analysis

13.4.4.2. LN-145 (Iovance Biotherapeutics)

13.4.4.2.1. Sales Forecast (USD Million)

13.4.4.2.2. Net Present Value (USD Million)

13.4.4.2.3. Value Creation Analysis

13.4.4.3. LTX-315 and TILs (Lytix Biopharma)

13.4.4.3.1. Sales Forecast (USD Million)

13.4.4.3.2. Net Present Value (USD Million)

13.4.4.3.3. Value Creation Analysis

13.4.4.4. TILs (Prometheus Laboratories)

13.4.4.4.1. Sales Forecast (USD Million)

13.4.4.4.2. Net Present Value (USD Million)

13.4.4.4.3. Value Creation Analysis

13.4.4.5. Donor Lymphocyte Infusion (Incyte)

13.4.4.5.1. Sales Forecast (USD Million)

13.4.4.5.2. Net Present Value (USD Million)

13.4.4.5.3. Value Creation Analysis

13.4.4.6. ITIL-168 (Instil Bio)

13.4.4.6.1. Sales Forecast (USD Million)

13.4.4.6.2. Net Present Value (USD Million)

13.4.4.6.3. Value Creation Analysis

13.4.4.7. IOV-2001 (Iovance Biotherapeutics)

13.4.4.7.1. Sales Forecast (USD Million)

13.4.4.7.2. Net Present Value (USD Million)

13.4.4.7.3. Value Creation Analysis

13.4.4.8. TILs (CAR-T (Shanghai) Cell Biotechnology)

13.4.4.8.1. Sales Forecast (USD Million)

13.4.4.8.2. Net Present Value (USD Million)

13.4.4.8.3. Value Creation Analysis

13.4.4.9. TILs (Bristol-Myers Squibb)

13.4.4.9.1. Sales Forecast (USD Million)

13.4.4.9.2. Net Present Value (USD Million)

13.4.4.9.3. Value Creation Analysis

14. COMPANY PROFILES

14.1. Chapter Overview

14.2. Cellectis

14.3. Cellular Biomedicine Group

14.4. Iovance Biotherapeutics

14.5. Lytix Biopharma

14.6. Phio Pharmaceuticals

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

I would like to order

Product name: Global TIL Therapy Market (2nd Edition), 2023-2035: Distribution by Target Indication (Melanoma, Head and Neck Carcinoma, Chronic Lymphocytic Leukemia, Sarcoma, Hepatocellular Carcinoma, Breast Cancer, Acute Myeloid Leukemia and Cervical Carcinoma), Key Players and Key Geographical Regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

Product link: <https://marketpublishers.com/r/GD6529FEC45AEN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD6529FEC45AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970